Aug 21, 2025 2025 NF1 Conference Poster: PHASE 1 TRIAL OF NEXT GENERATION MEK1/2 INHIBITOR PAS-004 IN ADULTS WITH INOPERABLE PLEXIFORM NEUROFIBROMAS
Jun 2, 2025 ASCO 2025 Poster Presentation: Phase I dose-escalation study of the safety and pharmacokinetics of PAS-004, a macrocyclic MEK inhibitor, for the treatment of patients with MAPK pathway–driven advanced solid tumors
Jun 3, 2024 ASCO 2024 Poster Presentation: PAS-004: A novel macrocyclic MEK inhibitor inhibits cancer cell growth in vitro and tumor growth in mouse xenograft studies
